Drugs / Amoxicillin-Clavulanate potassium
Amoxicillin-Clavulanate potassium
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02630992 | Dec 2015 → Dec 2016 | otitis media | Nader Shaikh | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT00445497 Background | Jul 2007 → Jul 2010 | central nervous system neoplasm, lymphoma, neutropenia, small intestine cancer | Clatterbridge Centre for Oncology | Unknown | No outcome recorded |
| — | NCT02315547 Background | Jan 2015 → Dec 2023 | bronchiectasis | Guangzhou Institute of Respiratory Disease | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amoxicillin-Clavulanate potassium | “treated with amoxicillin clavulanate potassium (625mg bid)” NCT02315547 ↗ |
| Known as | A/C | “Amoxicillin-clavulanate (A/C) is currently the most effective oral antimicrobial in treating children with acute otitis media (AOM), but the standard dosage of 90 mg...” PMID 28438923 ↗ Jun 2017 |
| Known as | amoxicillin-clavulanate | “Amoxicillin-clavulanate (A/C) is currently the most effective oral antimicrobial in treating children with acute otitis media (AOM), but the standard dosage of 90 mg...” PMID 28438923 ↗ Jun 2017 |
| Route | Oral | “oral amoxicillin-clavulanate potassium” NCT00445497 ↗ |